BioLineRx Announces Will Present Safety, Efficacy Clinical Data for Novel Stem Cell Mobilization Treatment at EHA

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that positive safety and efficacy Phase 1 clinical data of its lead clinical candidate, BL-8040, as a novel approach for mobilization and collection of bone-marrow stem cells from the peripheral blood circulation, will be presented in an oral presentation at the 20th Annual Congress of the European Hematology Association (EHA) to be held June 11-14, 2015 in Vienna, Austria. Data to be presented include response rates and additional pharmacodynamic studies done on the collected cells. In addition, positive preclinical data from studies supporting BL-8040's mechanism of action as a treatment for acute myeloid leukemia (AML) will be highlighted in a poster presentation. The molecular and cellular mechanisms by which BL-8040 affects AML cells will be presented.BL-8040 will be featured in the following sessions:(Abstract # S800) Monotherapy Treatment with a Single Dose of the CXCR4 Antagonist BL-8040 as a Novel Method for Mobilization of Human HSPC and MSC; Results of a Phase 1 Healthy Volunteers StudyPresenter: Yaron Pereg, PhD – Project LeaderSession: Stem Cell Transplantation: ClinicalDate and Time: Sunday, June 14, 8:00 a.m. – 8:15 a.m. CESTLocation: Room Lehar 1 + 2(Abstract # P171) The CXCR4 Antagonist BL-8040 Directly Affects AML Blasts by Inducing their Terminal Differentiation and Blocking Survival SignalsPresenter: Yaron Pereg, PhD – Project LeaderSession: Acute Myeloid Leukemia - BiologyDate and Time: Friday, June 12, 5:15 p.m. – 6:45 p.m. CESTLocation: Poster area (Hall C)